Navigation Links
Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic

ATHENS, Ga., July 15 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, announced today a strategic equity investment by Cato BioVentures and a collaboration with Cato Research Ltd., its global contract research and development organization. The investment and collaboration will help support continued development of Abeome's lead ovarian cancer project.

Abeome's proprietary technology vastly improves the development of monoclonal antibodies and Abeome is deploying its technology to provide a shotgun approach to develop an array of antibodies for an ovarian cancer therapeutic target. The company has developed novel monoclonal antibodies to four ovarian cancer cell lines and has begun screening these antibodies in search of those which cause either cancer cell growth inhibition or death.

Joel Eisner, Ph.D., Associate Principal of Cato BioVentures, states, "We are fascinated with Abeome's ability to develop such a large library of monoclonal antibodies by use of their technology. They have pushed the bottleneck of therapeutic development to the screening step which will provide a broader selection of novel antibodies to more cancer targets."

Monoclonal antibodies have become the centerpiece of many high-profile therapeutic products. Their specificity to disease targets, like cancer, has drawn significant attention from the biotech community.

"Ovarian cancer is a dreadful disease which is frequently diagnosed at a very late stage of development. With no effective therapeutic drugs on the market to date, we expect to address this unmet medical need. Our technology improves the likelihood of finding that one-of-a-kind antibody that can make the difference," said Mike Wanner, President and CEO of Abeome. "We are excited to have Cato Research join our expanding team of professional experts to help us with this important project".

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance.

For more information on Abeome, visit .

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. and has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital(TM) in innovative therapeutics, medical devices, diagnostics and platform technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley.

For more information on Cato BioVentures, visit .

SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
2. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
3. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
4. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
7. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
8. Small Business Innovation Research Program Awards Grant to Biomoda
9. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
10. New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right
11. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Post Your Comments:
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... 2015  Array BioPharma Inc. (Nasdaq: ARRY ... Ron Squarer , will present at the ... The public is welcome to participate in the ... website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, ... p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... , 24. November 2015 Avery ... Pacemaker Systems, ist erfreut, die Berufung von ... bekannt geben zu können. ... --> Foto - ... (Schweden). Von 1984-1986 war er Fellow des ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased ... moderate facial wrinkling. While many patients are aware of the benefits of Botox® in ... delivers to those suffering with discomfort, soreness, and pain as a result of Jaw ...
(Date:11/25/2015)... ... ... Beddit® has launched a new Android app for use with ... more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes it ... a proprietary algorithm. Beddit analyzes the data to provide an easy to understand scientific ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... Md (PRWEB) , ... November 25, 2015 , ... ... Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for ... of this disease. The Periwinkle Pioneers, nominated by the public, will receive special ...
Breaking Medicine News(10 mins):